Reviewed by G2 as the complete engagement platform, SpotMe offers tons of interactivity to keep audiences engaged, featuring Q&A’s, applause, video breakout rooms, and one-to-one meetings. But SpotMe does feature mobile apps for greater accessibility. This means attendees don’t need to download an app to attend a webinar or event on their desktop. SpotMe and BigMarker share that they’re both browser-based. SpotMe is a digital experience and virtual event platform that strives to go beyond the basic webinar, offering full virtual event capabilities. We provide important key features and pricing information for other platforms to help you understand what webinar solution might be best for your company’s virtual event needs. The following are descriptions of titles of abstracts of medical journal articles that may be interesting or useful to those who are interested in further information about this topic.These abstracts can be searched Here.If you’re looking for BigMarker alternatives, we’ve listed the top rated competitors. But despite gains we are not there yet. Some of the more recent developments in this area have been discussed in detail in our Pancreatica Blog. And is seems likely that this big knowledge will eventually lead to practical results. It is a promising arena, as finding pancreatic cancer earlier would likely enable many more patients to avail themselves of surgery, for example. The amount of research into the area of finding a means of screening for or providing for the earlier diagnosis of pancreatic cancer has increased dramatically in the past decade. Researchers have looked at many tissues and access points to study these potential markers including in stool, pancreatic juice, saliva and blood. There have been many recent intriguing study results looking at patterns of various MiRNA types in pancreatic cancer. First characterized in the 1990s, MiRNAs are small (22 nucleotide) non-coding RNA molecules involved in genetic regulation. Some of these include cell surface associated mucins (MUC), carcinoembryonic antigen (CEA), and heat shock proteins (HSP).Īpart from the genome and proteome, another area of great recent research interest in screening and diagnostic markers for pancreatic cancer has been in that of MicroRNAs. Many other agents have been studied as screening and diagnostic markers without much success. Thus far, much has been learned but no universally recognized markers have been established through the study of protein patterns. There has been considerable research in this area to try to detect reliable protein patterns in pancreatic cancer that will allow for screening or earlier diagnosis. The whole of this array of proteins is called the proteome. However, it remains an area of great interest.Ī related area is represented by the many proteins that emanate from genetic instruction. And although there has been a big increase in knowledge about DNA mutations and specific genes involved in pancreatic cancer, thus far this has not translated (yet) into screening tests or a diagnostic marker for pancreatic cancer. Because of the development of genetic micro-array tools (that allow for a huge number of tests all at once), in the past decade there has been a remarkable increase in research looking for genetic fingerprints to aid in the screening for and earlier diagnosis of pancreatic cancer. Some of these well-known genes are k-ras, p53 and p16. There are mutations in specific DNA genes that are found commonly in pancreatic cancer. Currently, some oncologists appear to feel that the best use of the CA19-9 marker is as a guide to follow the disease and treatment process in a given individual patient. Approximately 10% of Caucasians lack the Lewis antigen, so in them the CA19-9 is not expressed. This marker is somewhat uneven in the diagnosis of pancreatic cancer, but can be quite elevated in those with pancreatic cancer. The best known of the blood markers for pancreatic cancer is CA19-9, a “carbohydrate associated antigen” also known as a sialylated Lewis (a) antigen. There is the beginning of the establishment of protocols involving periodic testing procedures at certain academic institutions to follow persons at high risk for pancreatic cancer, but these measures have not been well studied yet. Presently, there is no agreed upon screening test to aid in the identification or earlier diagnosis of pancreatic cancer (ductal adenocarcinoma of the pancreas) for the general population. Pancreatic Cancer Surgery and Whipple Procedure.
Pancreatic Cancer Screening Tests and Markers.Pancreatic Cancer Causes and Risk Factors.Neuroendocrine tumors, Islet-cell and Carcinoid tumors.Alternative, Complementary and Holistic Treatment.